A5048627921- Glioma Diagnosis and Treatment
- Brain Metastases and Treatment
- Epigenetics and DNA Methylation
- Cell Adhesion Molecules Research
- Cancer, Hypoxia, and Metabolism
- Histone Deacetylase Inhibitors Research
- Cancer Genomics and Diagnostics
- Radiomics and Machine Learning in Medical Imaging
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Meningioma and schwannoma management
- MicroRNA in disease regulation
- Cancer Research and Treatments
- Cancer-related Molecular Pathways
- Caveolin-1 and cellular processes
- Immune cells in cancer
- RNA modifications and cancer
- Neuroblastoma Research and Treatments
- DNA Repair Mechanisms
- Cancer Cells and Metastasis
- Cellular Mechanics and Interactions
- Cancer-related molecular mechanisms research
- Protein Degradation and Inhibitors
- Nanoplatforms for cancer theranostics
- Chromatin Remodeling and Cancer
University Hospital of Lausanne
2016-2025
University of Lausanne
2015-2024
Swiss Cancer Center Léman
2021-2022
Weatherford College
2022
Center for Cancer Research
2018
Massachusetts General Hospital
2018
Broad Institute
2018
Dana-Farber Cancer Institute
2017-2018
Heidelberg University
2010-2017
Inserm
2012-2017
Epigenetic silencing of the MGMT (O6-methylguanine–DNA methyltransferase) DNA-repair gene by promoter methylation compromises DNA repair and has been associated with longer survival in patients glioblastoma who receive alkylating agents.
Tumor-treating fields (TTFields) is an antimitotic treatment modality that interferes with glioblastoma cell division and organelle assembly by delivering low-intensity alternating electric to the tumor.To investigate whether TTFields improves progression-free overall survival of patients glioblastoma, a fatal disease commonly recurs at initial tumor site or in central nervous system.In this randomized, open-label trial, 695 whose was resected biopsied had completed concomitant...
<h3>Importance</h3> Glioblastoma is the most devastating primary malignancy of central nervous system in adults. Most patients die within 1 to 2 years diagnosis. Tumor-treating fields (TTFields) are a locoregionally delivered antimitotic treatment that interferes with cell division and organelle assembly. <h3>Objective</h3> To evaluate efficacy safety TTFields used combination temozolomide maintenance after chemoradiation therapy for glioblastoma. <h3>Design, Setting, Participants</h3> After...
Purpose Radiotherapy with concomitant and adjuvant temozolomide is the standard of care for newly diagnosed glioblastoma (GBM). O 6 -methylguanine-DNA methyltransferase (MGMT) methylation status may be an important determinant treatment response. Dose-dense (DD) results in prolonged depletion MGMT blood mononuclear cells possibly tumor. This trial tested whether DD improves overall survival (OS) or progression-free (PFS) patients GBM. Patients Methods phase III enrolled older than age 18...
In the setting of a prospective clinical trial, we determined predictive value methylation status O-6-methylguanine-DNA methyltransferase (MGMT) promoter for outcome in glioblastoma patients treated with alkylating agent temozolomide. Expression this excision repair enzyme has been associated resistance to chemotherapy.The MGMT tumor biopsies was evaluated 38 undergoing resection newly diagnosed and enrolled Phase II trial testing concomitant adjuvant temozolomide radiation. The epigenetic...
Purpose Glioblastomas are notorious for resistance to therapy, which has been attributed DNA-repair proficiency, a multitude of deregulated molecular pathways, and, more recently, the particular biologic behavior tumor stem-like cells. Here, we aimed identify profiles specific treatment current standard care concomitant chemoradiotherapy with alkylating agent temozolomide. Patients and Methods Gene expression 80 glioblastomas were interrogated associations therapy. treated within clinical...
Linkage analysis of ten Utah kindreds and one Texas kindred with multiple cases cutaneous malignant melanoma (CMM) provided evidence that a locus for familial susceptibility is in the chromosomal region 9p13-p22. The genetic markers analyzed reside candidate on chromosome 9p21, previously implicated by presence homozygous deletions tumors germline deletion an individual eight independent melanomas. Multipoint linkage was performed between (MLM) two short tandem repeat markers, D9S126...
Immune checkpoint inhibitors targeting programmed cell death 1 (PD1) or its ligand (PD-L1) showed activity in several cancer types. We performed immunohistochemistry for CD3, CD8, CD20, HLA-DR, phosphatase and tensin homolog (PTEN), PD-1, PD-L1 pyrosequencing assessment of the O6-methylguanine-methyltransferase (MGMT) promoter methylation status 135 glioblastoma specimens (117 initial resection, 18 first local recurrence). gene expression was analyzed 446 cases from The Cancer Genome Atlas....